Triple-negative breast cancer is a particularly difficult to treat and biologically aggressive disease with limited treatment options. However, a subset of patients with triple-negative tumours may respond to chemotherapy. Therefore, optimisation of chemotherapy regimens may be key in treating triple-negative breast cancer. Emerging treatment approaches include novel chemotherapeutic agents such as the epothilones. The epothilones are a group of novel microtubule-stabilising agents with demonstrated activity in anthracycline-/taxane-resistant triple-negative breast cancer, and ongoing trials are evaluating the combination of epothilones with targeted agents or inclusion of epothilones in novel combination regimens. Other interesting new treatment options include the PARP inhibitors, which are currently in clinical trials for triple-negative breast cancer.

Triple-negative breast cancer: current management and future options / Conte, Pierfranco; Guarneri, Valentina. - In: EUROPEAN JOURNAL OF CANCER. SUPPLEMENT. - ISSN 1359-6349. - STAMPA. - 7:(2009), pp. 14-18.

Triple-negative breast cancer: current management and future options.

CONTE, Pierfranco;GUARNERI, Valentina
2009

Abstract

Triple-negative breast cancer is a particularly difficult to treat and biologically aggressive disease with limited treatment options. However, a subset of patients with triple-negative tumours may respond to chemotherapy. Therefore, optimisation of chemotherapy regimens may be key in treating triple-negative breast cancer. Emerging treatment approaches include novel chemotherapeutic agents such as the epothilones. The epothilones are a group of novel microtubule-stabilising agents with demonstrated activity in anthracycline-/taxane-resistant triple-negative breast cancer, and ongoing trials are evaluating the combination of epothilones with targeted agents or inclusion of epothilones in novel combination regimens. Other interesting new treatment options include the PARP inhibitors, which are currently in clinical trials for triple-negative breast cancer.
7
14
18
Triple-negative breast cancer: current management and future options / Conte, Pierfranco; Guarneri, Valentina. - In: EUROPEAN JOURNAL OF CANCER. SUPPLEMENT. - ISSN 1359-6349. - STAMPA. - 7:(2009), pp. 14-18.
Conte, Pierfranco; Guarneri, Valentina
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1359634909700059-main.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 233.71 kB
Formato Adobe PDF
233.71 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/608396
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact